T CELLS MODIFIED W/ CHIMERIC ANTICEA IGTCR IN ADENOCARCINOMA

$0M01FY2000RRNIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Paper 39043348 Paper 38748923 Paper 37369338 Paper 36881901 Paper 36380854 Paper 35005320 Paper 34401721 Paper 33305291 Paper 32807060 Paper 32634120 Paper 32487558 Paper 32480292 Paper 31874800 Paper 30737489 Paper 30488086 Paper 30062523 Paper 29564978 Paper 29453204 Paper 29306517 Paper 29203126 Paper 29118087 Paper 28992987 Paper 28891869 Paper 28578922 Paper 28460625 Paper 27993381 Paper 27880813 Paper 27806157 Paper 27730376 Paper 27567763 Paper 27484667 Paper 26965745 Paper 26823553 Paper 26231556 Paper 26156513 Paper 25755084 Paper 25547768 Paper 25540981 Paper 25524529 Paper 25505219 Paper 25441251 Paper 25399733 Paper 25399731 Paper 25279500 Paper 25148234 Paper 25015701 Paper 24924404 Paper 24751931 Paper 24703486 Paper 24488144 Paper 24386232 Paper 24244518 Paper 23992673 Paper 23912579 Paper 23867958 Paper 23737549 Paper 23710672 Paper 23650531 Paper 23415471 Paper 23382191 Paper 23290268 Paper 23197727 Paper 23193213 Paper 23171375 Paper 23123437 Paper 23078574 Paper 23057654 Paper 22807666 Paper 22759345 Paper 22738084 Paper 22563105 Paper 22512461 Paper 22396081 Paper 22305345 Paper 22275085 Paper 22202188 Paper 22154509 Paper 22075273 Paper 22040840 Paper 21984582 Paper 21975315 Paper 21956413 Paper 21926285 Paper 21917874 Paper 21900379 Paper 21865351 Paper 21864891 Paper 21842407 Paper 21835040 Paper 21803291 Paper 21795455 Paper 21781981 Paper 21741057 Paper 21732900 Paper 21706019 Paper 21700412 Paper 21660636 Paper 21617185 Paper 21593494 Paper 21571254

Abstract

To assess the safety and tolerability of antiCEA modified T cells in cancer therapy, with or without IL-2; and to determine whether IL-2 changes the safety profiles of the modified T cells.

View original record on NIH RePORTER →